Chen Yongyi, Gong Wangang, Dai Wumin, Jiang Huifen, Xu Xiaohong
Department of Clinical Lab, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China.
Transl Cancer Res. 2021 Jun;10(6):2801-2811. doi: 10.21037/tcr-21-45.
E2Fs are genes that regulate DNA synthesis and the cell cycle by encoding a family of transcription factors. Increasing experimental evidence has revealed that E2Fs play key roles in tumor progression in various types of cancer.
We investigated the survival, expression and transcriptional data of E2F1/2/4 in gastric cancer (GC) patients using the immunohistochemistry assay, Kaplan-Meier Plotter, cBioPortal, String, and GEPIA databases. The plasma of GC patients was analyzed using the real-time reverse transcription polymerase chain reaction (RT-PCR) assay. The correlation between E2F1/2/4 expression and clinical features was analyzed using the quartile method. As well, the correlation between E2F1/2/4 and GC immune infiltration was also investigated using the TIMER database. Database of Immune Cell Expression (DICE) was also used to analyze correlations between SOX4 and immune responses.
RT-PCR and tissue immunohistochemistry confirmed that E2F1/2/4 was highly expressed in serum and GC tissue samples of GC patients, the expression of which was not affected by patient age and gender. Also, the survival analysis revealed that low levels of E2F1/2/4 expression were significantly associated with a longer overall survival (OS) in GC patients. E2F1/2/4 was correlated with patient prognosis and immune cell infiltration, including B cells, CD8 T cells, CD4 T cells, macrophages, neutrophils, and DCs in GC. Our findings indicated that E2F1/2/4 could be used as a prognostic biomarker and indicator of immune infiltration in GC.
This study revealed that E2F1/2/4 could be a promising indicator for tumor-associated immune infiltration and prognosis in GC patients.
E2F 基因通过编码一类转录因子来调节 DNA 合成和细胞周期。越来越多的实验证据表明,E2F 在各类癌症的肿瘤进展中发挥关键作用。
我们使用免疫组织化学检测、Kaplan-Meier Plotter、cBioPortal、String 和 GEPIA 数据库,研究了胃癌(GC)患者中 E2F1/2/4 的生存、表达和转录数据。采用实时逆转录聚合酶链反应(RT-PCR)检测分析 GC 患者的血浆。使用四分位数法分析 E2F1/2/4 表达与临床特征之间的相关性。此外,还使用 TIMER 数据库研究了 E2F1/2/4 与 GC 免疫浸润之间的相关性。免疫细胞表达数据库(DICE)也用于分析 SOX4 与免疫反应之间的相关性。
RT-PCR 和组织免疫组织化学证实,E2F1/2/4 在 GC 患者的血清和 GC 组织样本中高表达,其表达不受患者年龄和性别的影响。生存分析还显示,GC 患者中 E2F1/2/4 低表达与更长的总生存期(OS)显著相关。E2F1/2/4 与患者预后及免疫细胞浸润相关,包括 GC 中的 B 细胞、CD8 T 细胞、CD4 T 细胞、巨噬细胞、中性粒细胞和树突状细胞。我们的研究结果表明,E2F1/2/4 可作为 GC 患者预后生物标志物和免疫浸润指标。
本研究表明,E2F1/2/4 可能是 GC 患者肿瘤相关免疫浸润和预后的一个有前景的指标。